Институт стволовых клеток человека ISKJ

Институт стволовых клеток человека Financial Ratios 2006-2026 | ISKJ

Annual Financial Ratios Институт стволовых клеток человека

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006
Price Earnings Ratio, P/E	42.36	145.3	274.0	27.68	11.52	-17.45	-8.41	-12.16	-15.21	-62.53	99.14	-6.8	45.37	114.89	19.64	131.64	144.8	-
Price Sales Ratio, P/S	5.23	5.89	7.78	2.64	1.17	0.93	1.74	3.47	2.52	2.3	3.48	3.22	3.17	4.01	5.94	9.17	13.62	-
Price To Book Ratio, P/B	14.29	19.65	39.15	14.73	9.87	22.09	16.84	8.8	2.72	2.43	4.15	1.55	1.03	4.0	4.49	56.18	71.8	-
Price Earnings To Growth Ratio, PEG	0.17	5.55	-3.94	1.25	-0.03	0.26	1.13	-0.11	-0.05	0.33	-0.9	0.04	0.02	-1.33	0.03	13.16	-	-
Operating Cash Flow Per Share	4.69	2.53	3.51	0.72	2.34	0.26	-0.26	0.48	0.06	0.51	1.1	-0.35	0.59	0.0	0.73	0.5	0.08	-
Free Cash Flow Per Share	2.48	0.97	1.59	-0.42	-0.27	-0.21	-3.1	-0.41	-0.2	0.07	0.64	-1.02	0.16	-0.14	0.55	0.19	-0.04	-
Cash Per Share	6.17	3.25	2.73	1.7	2.54	2.73	1.72	5.04	2.8	2.77	1.47	0.36	0.24	1.17	2.57	0.07	0.09	-
Payout Ratio	-	-	-	-	-	-	-	-0.19	-	-	-	-	-	1.12	0.19	0.5	-	-
Dividend Yield	-	-	-	-	-	-	-	0.02	-	-	-	-	-	0.01	0.01	0.0	-	-
Current Ratio	1.99	1.74	1.77	1.04	1.05	1.15	0.71	1.18	0.86	0.89	0.66	0.82	1.02	1.47	2.41	0.41	1.0	0.95
Quick Ratio	1.59	1.18	1.11	0.62	0.69	0.81	0.48	1.04	0.74	0.76	0.62	0.73	0.88	1.38	2.36	0.35	0.91	0.87
Cash Ratio	0.97	0.51	0.52	0.19	0.18	0.16	0.19	0.6	0.12	0.19	0.06	0.13	0.17	0.7	2.0	0.09	0.23	0.12
Days Of Sales Outstanding, DSO	21.82	-	-	-	-	-	-	-	-	-	-	29.43	-	-	-	-	-	-
Days Of Inventory Outstanding, DIO	205.28	314.65	309.57	274.8	383.57	632.62	489.26	348.28	400.96	630.98	334.6	187.13	188.64	1451.81	270.24	537.47	1887.45	-
Days Of Payables Outstanding, DPO	48.44	93.94	128.87	114.55	183.58	557.57	287.45	475.79	148.59	115.17	358.41	166.17	347.4	942.75	819.86	8023.06	19236.82	-
Operating Cycle	227.1	314.65	309.57	274.8	383.57	632.62	489.26	348.28	400.96	630.98	334.6	216.56	188.64	1451.81	270.24	537.47	1887.45	-
Cash Conversion Cycle	178.66	220.71	180.69	160.24	199.99	75.05	201.82	-127.5	252.37	515.81	-23.81	50.39	-158.76	509.06	-549.62	-7485.59	-17349.37	-
Gross Profit Margin	0.71	0.77	0.75	0.71	0.8	0.88	0.81	0.83	0.85	0.92	0.96	0.9	0.89	0.99	0.97	0.98	0.99	-
Operating Profit Margin	0.2	0.1	0.08	0.14	0.22	0.18	-0.12	-0.37	-0.31	-0.14	0.1	-0.04	0.06	0.04	0.19	0.06	0.11	-
Pretax Profit Margin	0.15	0.03	0.02	0.09	0.12	-0.08	-0.26	-0.38	-0.19	0.0	0.07	-0.45	0.07	0.05	0.34	0.09	0.12	-
Net Profit Margin	0.12	0.04	0.03	0.1	0.1	-0.05	-0.21	-0.29	-0.17	-0.04	0.04	-0.47	0.07	0.03	0.3	0.07	0.09	-
Effective Tax Rate	0.08	0.21	-0.14	-0.11	-0.1	0.66	0.14	0.13	-0.04	104.76	0.39	-0.05	-0.09	0.32	0.12	0.22	0.26	-
Return On Assets, ROA	0.07	0.02	0.02	0.07	0.06	-0.03	-0.1	-0.11	-0.06	-0.02	0.02	-0.15	0.02	0.02	0.16	0.1	0.17	-
Return On Equity, ROE	0.34	0.14	0.14	0.53	0.86	-1.27	-2.0	-0.72	-0.18	-0.04	0.04	-0.23	0.02	0.03	0.23	0.43	0.5	-
Return On Capital Employed, ROCE	0.14	0.07	0.07	0.15	0.2	0.16	-0.12	-0.26	-0.23	-0.12	0.11	-0.01	0.02	0.04	0.14	0.36	0.53	-
Net Income Per Ebt	0.8	1.57	1.14	1.11	0.83	0.64	0.81	0.74	0.85	-82.46	0.54	1.05	0.95	0.71	0.89	0.79	0.77	-
Ebt Per Ebit	0.77	0.26	0.32	0.64	0.56	-0.46	2.19	1.04	0.63	-0.0	0.64	12.05	1.16	1.33	1.83	1.38	1.1	-
Ebit Per Revenue	0.2	0.1	0.08	0.14	0.22	0.18	-0.12	-0.37	-0.31	-0.14	0.1	-0.04	0.06	0.04	0.19	0.06	0.11	-
Debt Ratio	0.31	0.41	0.36	0.32	0.3	0.33	0.39	0.33	0.14	0.12	0.18	0.15	0.01	0.0	0.0	0.05	-	-
Debt Equity Ratio	1.57	2.44	2.63	2.51	4.3	13.86	8.09	2.25	0.4	0.29	0.37	0.23	0.01	0.0	0.0	0.19	-	-
Long Term Debt To Capitalization	0.46	0.64	0.68	0.47	0.59	0.92	0.88	0.67	0.08	-	0.09	0.09	0.0	-	-	-	-	-
Total Debt To Capitalization	0.61	0.71	0.72	0.72	0.81	0.93	0.89	0.69	0.29	0.23	0.27	0.18	0.01	0.0	0.0	0.16	-	-
Interest Coverage	-	1.64	1.82	3.66	4.34	3.88	-1.89	-5.31	-11.05	-4.29	2.31	-2.17	40.2	23.51	76.98	28.88	183.43	-
Cash Flow To Debt Ratio	0.55	0.26	0.46	0.11	0.41	0.05	-0.05	0.1	0.04	0.39	0.64	-0.18	4.03	7.67	5492.12	10.12	-	-
Company Equity Multiplier	5.08	6.0	7.4	7.78	14.17	41.62	20.57	6.76	2.89	2.38	2.07	1.53	1.21	1.53	1.41	4.13	2.98	3.15
Receivables Turnover	16.72	-	-	-	-	-	-	-	-	-	-	12.4	-	-	-	-	-	-
Payables Turnover	7.53	3.89	2.83	3.19	1.99	0.65	1.27	0.77	2.46	3.17	1.02	2.2	1.05	0.39	0.45	0.05	0.02	-
Inventory Turn Over	1.78	1.16	1.18	1.33	0.95	0.58	0.75	1.05	0.91	0.58	1.09	1.95	1.93	0.25	1.35	0.68	0.19	-
Fixed Asset Turnover	4.33	4.05	4.14	3.28	2.2	2.33	1.75	2.55	3.22	3.25	3.57	4.78	7.08	5.38	4.38	3.7	6.26	-
Asset Turnover	0.54	0.56	0.68	0.72	0.6	0.57	0.47	0.38	0.37	0.45	0.58	0.32	0.27	0.65	0.54	1.48	1.77	-
Operating Cash Flow Sales Ratio	0.32	0.19	0.24	0.05	0.21	0.03	-0.04	0.09	0.01	0.11	0.2	-0.08	0.16	0.0	0.3	0.32	0.08	-
Free Cash Flow Operating Cash Flow Ratio	0.53	0.38	0.45	-0.59	-0.12	-0.82	11.83	-0.86	-3.2	0.14	0.58	2.89	0.28	-73.52	0.75	0.37	-0.5	-
Cash Flow Coverage Ratios	0.55	0.26	0.46	0.11	0.41	0.05	-0.05	0.1	0.04	0.39	0.64	-0.18	4.03	7.67	5492.12	10.12	-	-
Short Term Coverage Ratios	1.97	2.06	1390.1	0.3	1.27	0.38	-0.4	0.93	0.05	0.39	0.91	-0.3	4.34	7.67	5492.12	10.12	-	-
Capital Expenditure Coverage Ratio	2.13	1.62	1.83	0.63	0.9	0.55	-0.09	0.54	0.24	1.16	2.39	-0.53	1.38	0.01	4.01	1.6	0.67	-
Dividend Paid And Capex Coverage Ratio	2.13	1.62	1.83	0.63	0.9	0.55	-0.09	0.41	0.24	1.16	2.39	-0.53	1.38	0.01	2.25	1.36	0.67	-
Dividend Payout Ratio	-	-	-	-	-	-	-	-0.19	-	-	-	-	-	1.12	0.19	0.5	-	-
Price To Free Cash Flows Ratio, P/FCF	31.03	79.42	72.09	-90.18	-47.45	-37.51	-3.71	-43.83	-53.32	153.57	30.4	-13.26	71.12	-91.33	26.39	77.5	-357.13	-
Price To Operating Cash Flows Ratio, P/OCF	16.45	30.42	32.73	53.13	5.55	30.74	-43.9	37.55	170.38	21.58	17.69	-38.3	19.71	6714.78	19.81	29.06	177.07	-
Price Cash Flow Ratio, P/CF	16.45	30.42	32.73	53.13	5.55	30.74	-43.9	37.55	170.38	21.58	17.69	-38.3	19.71	6714.78	19.81	29.06	177.07	-
Enterprise Value Multiple, EV	22.69	48.68	59.57	15.55	6.45	7.09	-431.98	-14.34	-14.4	22.99	24.41	105.48	32.0	44.55	13.32	80.54	99.64	-
Price Fair Value, P/FV	14.29	19.65	39.15	14.73	9.87	22.09	16.84	8.8	2.72	2.43	4.15	1.55	1.03	4.0	4.49	56.18	71.8	-

All numbers in RUB currency

Quarterly Financial Ratios Институт стволовых клеток человека

	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q3
Price Earnings Ratio, P/E	34.3 K	34.3 K	21.2 K	21.2 K	89.8 K	89.8 K	162 K	162 K	133 K	154 K	196	-484 K	24.9	71.1 K	24.8	3.07 M	40.9	6.05 K	0.003	16.8 K	6.54 K	6.76 K	-4.43 K	-5.12 K	10.7 K	10.2 K	-2.59	9.9	-9.21 K	-13.6 K	-53.8	-8.22	-	-68.5	-5.77 K	-5.66 K	21.4 K	21.3 K	-8.85 K	-9.84 K	15.9 K	5.34	-28 K	-25.7 K	-	12.3	-
Price Sales Ratio, P/S	15.3 K	15.3 K	15.5 K	15.5 K	18.4 K	18.4 K	22.2 K	22.2 K	25.6 K	29.6 K	13.5	25.1 K	5.01	10.1 K	4.99	8.13 K	2.98	3.87 K	0.002	4.94 K	3.49 K	3.6 K	3.4 K	3.93 K	4.86 K	4.63 K	6.07	7.84	8.04	9.39	12.9	16.6	-	21.3	9.87	9.68	9.23 K	9.18 K	8.91	9.91	12.2 K	10.9	14.3 K	13.2 K	-	8.59	-
Price To Book Ratio, P/B	13.2 K	13.2 K	11.6 K	11.6 K	15 K	15 K	20.1 K	20.1 K	24.1 K	27.8 K	35.9 K	33.3 K	12.5 K	12.6 K	14.3 K	13.2 K	8.7 K	4.05 K	9.87	10 K	4.37 K	4.52 K	22.1 K	25.5 K	6.13 K	5.84 K	16.8	7.31	8.22 K	8.06 K	8.8	8.57	-	7.1	2.72 K	2.67 K	1.97 K	1.96 K	2.43 K	2.7 K	2.38 K	1.43	4.15 K	1.7 K	-	1.41	-
Price Earnings To Growth Ratio, PEG	-	-1.03 K	-	60.5	-	898	-	-	-	-1.54 K	-	4.84 K	0.0	-711	-	-30.7 K	0.001	-60.5	0.0	-503	-	-38.6	-	17.1	-	-102	0.006	-0.0	-	136	0.633	0.325	-	-0.004	-	9.43	-	-160	-	39.4	-159	-0.0	-	-	-	-	-
Operating Cash Flow Per Share	0.001	0.001	0.003	0.003	0.0	0.0	0.001	0.001	0.0	0.0	2.71	0.001	0.51	0.0	-	0.001	-	-0.0	-	0.001	0.0	0.0	-0.0	-0.0	0.001	0.001	0.54	-0.173	-0.0	-0.0	1.88	-1.11	-	-0.316	0.0	0.0	-0.0	-0.0	-0.0	-	0.0	-	0.0	-	-	-	-
Free Cash Flow Per Share	0.0	0.0	0.002	0.002	-0.0	-0.0	0.001	0.001	-0.0	-0.0	0.763	0.001	-0.225	-0.0	-	0.001	-	-0.001	-	-0.0	0.0	0.0	-0.0	-0.0	-0.0	-0.0	0.323	-0.854	-0.002	-0.001	1.2	-1.2	-	-0.316	0.0	0.0	-0.0	-0.0	-0.0	-	0.0	-	0.0	-	-	-	-
Cash Per Share	0.005	0.005	0.008	0.008	0.005	0.005	0.003	0.003	0.001	0.001	0.003	0.002	0.001	0.001	0.002	0.001	0.003	0.002	2.54	0.002	0.002	0.002	0.003	0.003	0.003	0.003	1.72	2.66	0.004	0.006	5.04	4.75	-	2.39	0.003	0.003	0.003	0.002	0.002	0.002	0.003	2.62	0.001	0.001	-	1.16	-
Payout Ratio	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Dividend Yield	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.88	1.88	1.99	1.99	2.09	2.09	1.74	1.74	1.98	1.98	1.77	1.77	1.32	1.32	1.04	1.04	1.41	1.41	1.05	1.05	1.22	1.22	1.15	1.15	0.804	0.804	0.705	0.934	0.946	1.27	1.18	1.28	0.699	0.697	0.863	0.863	0.953	0.953	0.895	0.895	0.939	0.852	0.662	0.783	1.05	0.826	0.895
Quick Ratio	1.41	1.41	1.59	1.59	1.61	1.61	1.18	1.18	1.21	1.21	1.11	1.11	0.689	0.689	0.616	0.616	0.829	0.829	0.691	0.691	0.848	0.848	0.814	0.814	0.624	0.624	0.483	0.775	0.808	1.14	1.04	1.17	0.55	0.697	0.738	0.738	0.802	0.802	0.756	0.756	0.895	0.817	0.616	0.727	0.923	0.768	0.831
Cash Ratio	0.686	0.686	0.971	0.971	0.796	0.796	0.51	0.51	0.202	0.202	0.519	0.519	0.12	0.12	0.193	0.193	0.344	0.344	0.184	0.184	0.143	0.143	0.156	0.156	0.135	0.135	0.191	0.235	0.367	0.668	0.598	0.694	0.053	0.069	0.121	0.121	0.161	0.161	0.194	0.194	0.276	0.142	0.056	0.02	0.224	0.016	0.088
Days Of Sales Outstanding, DSO	20.8	20.8	19.7	19.7	-	30.1	-	19.8	-	23	0.012	24	0.016	31.6	-	25.7	-	21.5	-	24.7	-	23	-	22.4	-	30.4	-	-	-	0.053	-	34.6	-	-	-	0.027	-	30.7	0.018	0.018	-	-	49.2	-	-	-	-
Days Of Inventory Outstanding, DIO	244	244	171	171	239	239	153	153	212	212	0.05	184	0.056	206	0.052	130	0.051	731	0.061	250	352	352	476	476	265	265	279	520	198	142	291	170	131	-	129	129	207	207	182	182	74.2	15.3	101	107	-	34.3	-
Days Of Payables Outstanding, DPO	27.1	27.1	40.4	40.4	161	36	45.5	23.1	104	51	0.021	27	0.02	73	0.022	19.7	0.02	87.2	0.029	59.3	168	168	419	276	215	179	164	408	291	188	397	124	110	128	47.6	38	40.7	20.4	14.2	14.2	92.8	315	40.2	1.29 K	-	384	-
Operating Cycle	264	264	191	191	239	269	153	172	212	235	0.062	208	0.072	238	0.052	156	0.051	753	0.061	274	352	375	476	498	265	296	279	520	198	142	291	205	131	-	129	129	207	238	182	182	74.2	15.3	150	107	-	34.3	-
Cash Conversion Cycle	237	237	150	150	78.3	233	107	149	109	184	0.041	181	0.052	165	0.03	136	0.031	665	0.032	215	184	207	56.4	223	50.5	117	115	112	-92.6	-45.8	-106	80.5	21.4	-128	80.9	90.6	167	218	168	168	-18.6	-299	110	-1.18 K	-	-349	-
Gross Profit Margin	0.75	0.75	0.681	0.681	0.736	0.736	0.572	0.572	0.629	0.629	0.296	0.616	0.274	0.602	0.274	0.489	0.244	0.854	0.435	0.724	0.797	0.797	0.852	0.852	0.756	0.756	0.719	0.899	1.0	1.0	0.811	0.731	0.606	0.865	1.0	1.0	0.688	0.688	1.0	1.0	0.796	0.331	0.868	0.868	-	0.647	-
Operating Profit Margin	0.223	0.223	0.228	0.228	0.169	0.169	0.077	0.077	0.122	0.122	0.044	0.086	0.078	0.118	0.093	0.096	0.075	0.303	0.213	0.239	0.189	0.189	0.343	0.343	-0.011	-0.011	-0.043	0.03	-0.0	-0.0	-0.37	-0.755	-0.425	0.041	-0.0	-0.0	-0.121	-0.121	-0.0	-0.0	-0.082	0.031	0.002	0.002	-	0.426	-
Pretax Profit Margin	0.136	0.136	0.225	0.225	0.07	0.07	-0.0	-0.0	0.057	0.057	0.018	0.013	0.043	0.039	0.043	0.02	0.021	0.178	0.178	0.083	0.166	0.166	-0.231	-0.231	0.093	0.093	-0.595	0.124	-0.0	-0.0	-0.176	-0.73	-0.575	-0.088	-0.0	-0.0	0.116	0.116	-0.0	-0.0	0.24	0.668	-0.115	-0.115	-	0.228	-
Net Profit Margin	0.112	0.112	0.183	0.183	0.051	0.051	0.034	0.034	0.048	0.048	0.017	-0.013	0.05	0.035	0.05	0.001	0.018	0.16	0.204	0.074	0.133	0.133	-0.192	-0.192	0.113	0.113	-0.585	0.198	-0.0	-0.0	-0.06	-0.506	-0.514	-0.078	-0.0	-0.0	0.108	0.108	-0.0	-0.0	0.192	0.511	-0.128	-0.128	-	0.175	-
Effective Tax Rate	0.022	0.022	0.056	0.056	0.17	0.17	-55.1	-55.1	0.017	0.017	0.018	0.025	-0.181	199	-0.181	0.139	0.135	146	-0.146	292	0.017	0.017	-0.359	-0.359	235	235	0.067	-0.625	-0.075	-0.01	0.339	0.197	-0.006	0.121	-0.02	-0.02	0.214	0.214	-0.12	-0.12	0.282	0.235	-0.174	-0.174	-	0.233	-
Return On Assets, ROA	0.017	0.017	0.027	0.027	0.007	0.007	0.005	0.005	0.007	0.007	6.2	-0.002	18.7	0.007	18.5	0.0	7.24	0.023	66	0.012	0.018	0.018	-0.03	-0.03	0.015	0.015	-0.079	0.024	-0.023	-0.018	-0.006	-0.042	-0.074	-0.009	-0.041	-0.041	0.01	0.01	-0.029	-0.029	0.02	0.045	-0.018	-0.012	-	0.02	-
Return On Equity, ROE	0.096	0.096	0.137	0.137	0.042	0.042	0.031	0.031	0.045	0.045	45.9	-0.017	125	0.044	144	0.001	53.2	0.168	934	0.15	0.167	0.167	-1.25	-1.25	0.143	0.143	-1.62	0.185	-0.223	-0.148	-0.041	-0.261	-0.278	-0.026	-0.118	-0.118	0.023	0.023	-0.069	-0.069	0.037	0.067	-0.037	-0.017	-	0.029	-
Return On Capital Employed, ROCE	0.042	0.042	0.043	0.043	0.028	0.028	0.014	0.014	0.022	0.022	20.3	0.02	39.6	0.03	54.1	0.032	41.9	0.061	106	0.059	0.036	0.036	0.085	0.085	-0.003	-0.003	-0.012	0.006	-0.033	-0.059	-0.069	-0.108	-0.138	0.01	-0.093	-0.093	-0.019	-0.019	-0.042	-0.042	-0.014	0.004	0.0	0.0	-	0.064	-
Net Income Per Ebt	0.82	0.82	0.816	0.816	0.734	0.734	-173	-173	0.85	0.85	0.982	-1.02	1.18	0.914	1.18	0.032	0.865	0.899	1.15	0.885	0.803	0.803	0.83	0.83	1.21	1.21	0.983	1.6	0.846	0.68	0.34	0.693	0.893	0.879	0.871	0.871	0.928	0.928	1.12	1.12	0.8	0.765	1.11	1.11	-	0.767	-
Ebt Per Ebit	0.609	0.609	0.984	0.984	0.415	0.415	-0.003	-0.003	0.463	0.463	0.395	0.148	0.545	0.328	0.458	0.213	0.281	0.587	0.833	0.349	0.877	0.877	-0.674	-0.674	-8.84	-8.84	13.9	4.18	1.51	0.797	0.475	0.966	1.35	-2.13	1.01	1.01	-0.96	-0.96	1.12	1.12	-2.93	21.4	-74.9	-74.9	-	0.535	-
Ebit Per Revenue	0.223	0.223	0.228	0.228	0.169	0.169	0.077	0.077	0.122	0.122	0.044	0.086	0.078	0.118	0.093	0.096	0.075	0.303	0.213	0.239	0.189	0.189	0.343	0.343	-0.011	-0.011	-0.043	0.03	-0.0	-0.0	-0.37	-0.755	-0.425	0.041	-0.0	-0.0	-0.121	-0.121	-0.0	-0.0	-0.082	0.031	0.002	0.002	-	0.426	-
Debt Ratio	0.315	0.315	0.309	0.309	0.345	0.345	0.407	0.407	0.356	0.356	0.355	0.355	0.318	0.318	0.323	0.323	0.329	0.329	0.303	0.303	0.364	0.364	0.333	0.333	0.36	0.36	0.393	0.403	0.4	0.393	0.333	0.396	0.099	0.142	0.138	0.138	0.139	0.139	0.123	0.123	0.161	0.098	0.177	0.121	0.124	0.143	0.111
Debt Equity Ratio	1.82	1.82	1.57	1.57	2.13	2.13	2.44	2.44	2.25	2.25	2.63	2.63	2.14	2.14	2.51	2.51	2.41	2.41	4.3	3.83	3.38	3.38	13.9	13.9	3.47	3.47	8.09	3.13	3.94	3.28	2.25	2.43	0.368	0.413	0.399	0.399	0.329	0.329	0.292	0.292	0.3	0.146	0.367	0.172	0.175	0.21	0.156
Long Term Debt To Capitalization	0.503	0.503	0.461	0.461	0.606	0.606	0.638	0.638	0.647	0.647	0.678	0.678	0.473	0.473	0.474	0.474	0.496	0.496	0.593	0.564	0.69	0.69	0.923	0.923	0.744	0.744	0.876	0.737	0.781	0.746	0.667	0.66	0.067	0.063	0.079	0.079	0.067	0.067	-	-	0.055	0.043	0.095	0.055	0.063	0.082	0.051
Total Debt To Capitalization	0.646	0.646	0.611	0.611	0.68	0.68	0.709	0.709	0.693	0.693	0.724	0.724	0.681	0.681	0.715	0.715	0.707	0.707	0.811	0.793	0.772	0.772	0.933	0.933	0.777	0.777	0.89	0.758	0.798	0.766	0.692	0.709	0.269	0.292	0.285	0.285	0.248	0.248	0.226	0.226	0.231	0.127	0.268	0.147	0.149	0.173	0.135
Interest Coverage	-	-	-	-	-	-	-	-	-	-	0.779	-	1.55	-	1.84	-	1.39	-	5.97	-	-	-	-	-	-	-	-0.727	0.461	-	-	-2.33	-21.9	-11.9	1.07	-	-	-	-	-	-	-	0.871	-	-	-	11.4	-
Cash Flow To Debt Ratio	0.072	0.072	0.243	0.243	0.032	0.032	0.104	0.104	0.038	0.038	323	0.184	77.8	0.056	-	0.127	-	-0.067	-	0.18	0.029	0.029	-0.082	-0.082	0.1	0.1	0.098	-0.031	-0.046	-0.062	0.407	-0.213	0.024	-0.204	0.216	0.216	-0.192	-0.192	-0.142	-	0.247	-	0.058	-	-	-	-
Company Equity Multiplier	5.8	5.8	5.08	5.08	6.18	6.18	6	6	6.33	6.33	7.4	7.4	6.72	6.72	7.78	7.78	7.34	7.34	14.2	12.6	9.29	9.29	41.6	41.6	9.65	9.65	20.6	7.77	9.86	8.34	6.76	6.14	3.73	2.92	2.89	2.89	2.37	2.37	2.38	2.38	1.86	1.49	2.07	1.42	1.41	1.47	1.41
Receivables Turnover	4.33	4.33	4.57	4.57	-	2.99	-	4.55	-	3.91	7.52 K	3.75	5.68 K	2.85	-	3.5	-	4.19	-	3.65	-	3.91	-	4.01	-	2.96	-	-	-	1.68 K	-	2.6	-	-	-	3.37 K	-	2.94	4.9 K	4.9 K	-	-	1.83	-	-	-	-
Payables Turnover	3.32	3.32	2.23	2.23	0.56	2.5	1.98	3.9	0.868	1.77	4.29 K	3.34	4.5 K	1.23	4.15 K	4.56	4.58 K	1.03	3.1 K	1.52	0.537	0.537	0.215	0.327	0.419	0.504	0.549	0.221	0.309	0.479	0.227	0.724	0.82	0.704	1.89	2.37	2.21	4.42	6.34	6.34	0.97	0.286	2.24	0.07	-	0.235	-
Inventory Turn Over	0.369	0.369	0.526	0.526	0.376	0.376	0.59	0.59	0.424	0.424	1.79 K	0.488	1.59 K	0.437	1.73 K	0.691	1.77 K	0.123	1.48 K	0.361	0.256	0.256	0.189	0.189	0.339	0.339	0.322	0.173	0.454	0.634	0.309	0.529	0.686	-	0.7	0.7	0.434	0.434	0.494	0.494	1.21	5.88	0.891	0.844	-	2.62	-
Fixed Asset Turnover	1.01	1.01	1.18	1.18	1.03	1.03	1.1	1.1	0.952	0.952	2.19 K	1.09	1.82 K	0.91	1.69 K	0.955	1.77 K	0.636	1.19 K	0.594	0.484	0.484	0.635	0.635	0.546	0.546	0.503	0.444	395	730	0.686	0.913	1.17	1.03	823	823	0.758	0.758	838	838	1.06	1	0.869	0.99	-	1.23	-
Asset Turnover	0.149	0.149	0.147	0.147	0.132	0.132	0.151	0.151	0.149	0.149	359	0.18	371	0.186	368	0.209	398	0.143	324	0.161	0.135	0.135	0.156	0.156	0.131	0.131	0.135	0.12	104	103	0.101	0.084	0.145	0.115	95.4	95.4	0.09	0.09	115	115	0.105	0.088	0.14	0.091	-	0.111	-
Operating Cash Flow Sales Ratio	0.152	0.152	0.512	0.512	0.084	0.084	0.28	0.28	0.091	0.091	0.319	0.364	0.067	0.096	-	0.196	-	-0.154	-	0.339	0.079	0.079	-0.174	-0.174	0.275	0.275	0.285	-0.103	-0.0	-0.0	1.34	-1.01	0.016	-0.253	0.0	0.0	-0.296	-0.296	-0.0	-	0.381	-	0.074	-	-	-	-
Free Cash Flow Operating Cash Flow Ratio	0.481	0.481	0.637	0.637	-0.249	-0.249	0.777	0.777	-1.06	-1.06	0.281	0.562	-0.442	-0.004	-	0.703	-	1.7	-	-0.084	0.735	0.735	0.093	0.093	-0.127	-0.127	0.598	4.94	7.55	1.56	0.637	1.08	-3.98	1	0.747	0.747	1.15	1.15	1.84	-	0.859	-	2.22	-	-	-	-
Cash Flow Coverage Ratios	0.072	0.072	0.243	0.243	0.032	0.032	0.104	0.104	0.038	0.038	323	0.184	77.8	0.056	-	0.127	-	-0.067	-	0.18	0.029	0.029	-0.082	-0.082	0.1	0.1	0.098	-0.031	-0.046	-0.062	0.407	-0.213	0.024	-0.204	0.216	0.216	-0.192	-0.192	-0.142	-	0.247	-	0.058	-	-	-	-
Short Term Coverage Ratios	0.328	0.328	0.867	0.867	0.307	0.307	0.807	0.807	-	-	985 K	563	251	0.18	-	0.347	-	-0.206	-	0.552	0.427	0.427	-0.603	-0.603	0.626	0.626	0.828	-0.304	-0.493	-0.597	3.63	-1.05	0.03	-0.244	0.275	0.275	-0.246	-0.246	-0.143	-	0.311	-	0.083	-	-	-	-
Capital Expenditure Coverage Ratio	1.93	1.93	2.75	2.75	0.801	0.801	4.49	4.49	0.486	0.486	1.39	2.28	0.693	0.996	-	3.37	-	-1.43	-	0.922	3.78	3.78	-1.1	-1.1	0.887	0.887	2.49	-0.254	-0.153	-1.77	2.75	-12.2	0.201	-	3.96	3.96	-6.64	-6.64	-1.2	-	7.08	-	0.818	-	-	-	-
Dividend Paid And Capex Coverage Ratio	1.93	1.93	2.75	2.75	0.801	0.801	4.49	4.49	0.486	0.486	1.39	2.28	0.693	0.996	-	3.37	-	-1.43	-	0.922	3.78	3.78	-1.1	-1.1	0.887	0.887	2.49	-0.254	-0.153	-1.77	2.75	-12.2	0.201	-	3.96	3.96	-6.64	-6.64	-1.2	-	7.08	-	0.818	-	-	-	-
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Price To Free Cash Flows Ratio, P/FCF	210 K	210 K	47.7 K	47.7 K	-877 K	-877 K	102 K	102 K	-266 K	-307 K	151	122 K	-170	-26.6 M	-	59 K	-	-14.8 K	-	-173 K	60.2 K	62.1 K	-210 K	-243 K	-139 K	-133 K	35.6	-15.3	-6 K	-25.3 K	15.1	-15.3	-	-84.1	42.3 K	41.5 K	-27.1 K	-27 K	-32 K	-	37.4 K	-	87.1 K	-	-	-	-
Price To Operating Cash Flows Ratio, P/OCF	101 K	101 K	30.4 K	30.4 K	218 K	218 K	79.2 K	79.2 K	281 K	325 K	42.4	68.8 K	75.1	105 K	-	41.5 K	-	-25.1 K	-	14.6 K	44.2 K	45.7 K	-19.5 K	-22.6 K	17.7 K	16.9 K	21.3	-75.8	-45.3 K	-39.5 K	9.6	-16.5	-	-84.1	31.6 K	31 K	-31.2 K	-31 K	-58.7 K	-	32.1 K	-	194 K	-	-	-	-
Price Cash Flow Ratio, P/CF	101 K	101 K	30.4 K	30.4 K	218 K	218 K	79.2 K	79.2 K	281 K	325 K	42.4	68.8 K	75.1	105 K	-	41.5 K	-	-25.1 K	-	14.6 K	44.2 K	45.7 K	-19.5 K	-22.6 K	17.7 K	16.9 K	21.3	-75.8	-45.3 K	-39.5 K	9.6	-16.5	-	-84.1	31.6 K	31 K	-31.2 K	-31 K	-58.7 K	-	32.1 K	-	194 K	-	-	-	-
Enterprise Value Multiple, EV	59.4 K	59.4 K	60.4 K	60.4 K	85 K	85 K	207 K	207 K	165 K	191 K	117	161 K	34.8	61.1 K	63.9	57.9 K	52	10.8 K	0.017	17.3 K	14.1 K	14.6 K	9.56 K	11 K	66.3 K	63.2 K	-21.1	39.6	-49.2 K	-39.4 K	415	-29.9	-0.884	-448	-24.4 K	-23.9 K	-194 K	-193 K	-72 K	-80 K	-1.11 M	16.5	173 K	159 K	-	37.1	-
Price Fair Value, P/FV	13.2 K	13.2 K	11.6 K	11.6 K	15 K	15 K	20.1 K	20.1 K	24.1 K	27.8 K	35.9 K	33.3 K	12.5 K	12.6 K	14.3 K	13.2 K	8.7 K	4.05 K	9.87	10 K	4.37 K	4.52 K	22.1 K	25.5 K	6.13 K	5.84 K	16.8	7.31	8.22 K	8.06 K	8.8	8.57	-	7.1	2.72 K	2.67 K	1.97 K	1.96 K	2.43 K	2.7 K	2.38 K	1.43	4.15 K	1.7 K	-	1.41	-

All numbers in RUB currency

Multiples are an important financial analysis tool for the company Институт стволовых клеток человека, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios

Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Biotechnology industry

Issuer	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	-	2.43 %	$ 254 M	Germany
Alector ALEC	$ 2.08	-14.4 %	$ 214 M	USA
Acer Therapeutics ACER	-	2.71 %	$ 14 M	USA
Altimmune ALT	$ 4.2	-2.67 %	$ 298 M	USA
Apellis Pharmaceuticals APLS	$ 20.24	-3.44 %	$ 2.55 B	USA
Aptorum Group Limited APM	$ 0.8	1.87 %	$ 4.36 M	China
Aprea Therapeutics APRE	$ 0.88	-3.72 %	$ 3.18 M	USA
Aptevo Therapeutics APVO	$ 7.2	-1.64 %	$ 1.99 M	USA
I-Mab IMAB	-	-	$ 866 M	China
Aquestive Therapeutics AQST	$ 4.1	2.37 %	$ 356 M	USA
Alexion Pharmaceuticals, Inc. ALXN	-	-	$ 40.3 B	USA
AgeX Therapeutics AGE	-	-10.17 %	$ 12.2 K	USA
Arcturus Therapeutics Holdings ARCT	$ 8.35	1.46 %	$ 225 M	Israel
Ardelyx ARDX	$ 6.37	-2.75 %	$ 1.54 B	USA
Biophytis SA BPTS	-	-13.47 %	$ 169 M	France
Aeglea BioTherapeutics AGLE	-	-	$ 1.01 B	USA
argenx SE ARGX	$ 756.71	-1.33 %	$ 25 B	Niderland
Armata Pharmaceuticals ARMP	$ 10.91	1.58 %	$ 394 M	USA
Applied Genetic Technologies Corporation AGTC	-	-	$ 26.5 M	USA
Arcutis Biotherapeutics ARQT	$ 25.33	-6.1 %	$ 3.22 B	USA
EyeGate Pharmaceuticals, Inc. EYEG	-	-1.52 %	$ 24.7 M	USA
Midatech Pharma plc MTP	-	-18.52 %	$ 27.3 M	Britain
Artelo Biosciences ARTL	$ 1.15	-3.36 %	$ 2.32 M	USA
Arvinas ARVN	$ 12.97	-2.3 %	$ 920 M	USA
Arrowhead Pharmaceuticals ARWR	$ 61.74	-2.42 %	$ 8.26 B	USA
Ascendis Pharma A/S ASND	$ 231.56	-0.83 %	$ 5 B	Danmark
Alterity Therapeutics Limited ATHE	$ 3.39	-1.63 %	$ 8.16 B	Australia
Actinium Pharmaceuticals ATNM	$ 1.17	-0.85 %	$ 35.2 M	USA
Atossa Therapeutics ATOS	$ 4.39	-0.9 %	$ 553 M	USA
Atara Biotherapeutics ATRA	$ 5.01	-7.47 %	$ 37.5 M	USA
Aurinia Pharmaceuticals AUPH	$ 14.14	-0.21 %	$ 1.9 B	Canada
ARCA biopharma ABIO	-	1052.0 %	$ 415 M	USA
Acorda Therapeutics ACOR	-	-24.86 %	$ 820 K	USA
Autolus Therapeutics plc AUTL	$ 1.68	-1.75 %	$ 429 M	Britain
Acasti Pharma ACST	-	4.01 %	$ 150 M	Canada
Atea Pharmaceuticals AVIR	$ 4.69	0.21 %	$ 395 M	USA
Adverum Biotechnologies ADVM	-	-	$ 86.2 M	USA
AIkido Pharma AIKI	-	1.93 %	$ 17.4 M	USA
Anavex Life Sciences Corp. AVXL	$ 4.54	2.44 %	$ 387 M	USA
Akero Therapeutics AKRO	-	-	$ 3.67 B	USA
Akouos AKUS	-	0.23 %	$ 488 M	USA
Albireo Pharma ALBO	-	-0.23 %	$ 916 M	USA
Axon Enterprise AXON	$ 570.5	5.18 %	$ 43.2 B	USA
Axsome Therapeutics AXSM	$ 162.28	-0.98 %	$ 8.07 B	USA
Allena Pharmaceuticals ALNA	-	3.16 %	$ 1.9 M	USA
Aytu BioScience AYTU	$ 2.56	-0.58 %	$ 16.1 M	USA
Aileron Therapeutics ALRN	-	10.36 %	$ 9.8 M	USA
AlloVir ALVR	-	4.14 %	$ 49.1 M	USA
Alpine Immune Sciences ALPN	-	-	$ 2.17 B	USA

Институт стволовых клеток человека Financial Ratios 2006-2026 | ISKJ

Annual Financial Ratios Институт стволовых клеток человека

Price Earnings Ratio, P/E

Price Sales Ratio, P/S

Price To Book Ratio, P/B

Price Earnings To Growth Ratio, PEG

Operating Cash Flow Per Share

Free Cash Flow Per Share

Cash Per Share

Payout Ratio

Dividend Yield

Current Ratio

Quick Ratio

Cash Ratio

Days Of Sales Outstanding, DSO

Days Of Inventory Outstanding, DIO

Days Of Payables Outstanding, DPO

Operating Cycle

Cash Conversion Cycle

Gross Profit Margin

Operating Profit Margin

Pretax Profit Margin

Net Profit Margin

Effective Tax Rate

Return On Assets, ROA

Return On Equity, ROE

Return On Capital Employed, ROCE

Net Income Per Ebt

Ebt Per Ebit

Ebit Per Revenue

Debt Ratio

Debt Equity Ratio

Long Term Debt To Capitalization

Total Debt To Capitalization

Interest Coverage

Cash Flow To Debt Ratio

Company Equity Multiplier

Receivables Turnover

Payables Turnover

Inventory Turn Over

Fixed Asset Turnover

Asset Turnover

Operating Cash Flow Sales Ratio

Free Cash Flow Operating Cash Flow Ratio

Cash Flow Coverage Ratios

Short Term Coverage Ratios

Capital Expenditure Coverage Ratio

Dividend Paid And Capex Coverage Ratio

Dividend Payout Ratio

Price To Free Cash Flows Ratio, P/FCF

Price To Operating Cash Flows Ratio, P/OCF

Price Cash Flow Ratio, P/CF

Enterprise Value Multiple, EV

Price Fair Value, P/FV